<p>多倫多，2025 年 12 月 24 日（GLOBE NEWSWIRE）-- <strong>Profound Medical Corp. (NASDAQ:PROF; TSX:PRN)</strong>（“Profound” 或 “公司”）欣然宣佈，已增加其於 2025 年 12 月 19 日之前宣佈的私募配售規模（“發行”），以便容納一位長期現有投資者的參與。</p>
<p>公司現在將在此次發行中籌集最多 645 萬美元的毛收益，通過發行最多 921,428 股普通股，價格為每股 7.00 美元。</p>
<p>根據此次發行出售的普通股將受到四個月加一天的持有期限制，從發行的成交日期開始計算。預計此次發行的成交將在 2025 年 12 月 30 日或之前進行。</p>
<p>公司打算將此次發行的淨收益用於擴大銷售和市場營銷、營運資金、研發、戰略交易和一般企業用途。</p>
<p>此次發行下不會向美國購買者出售任何證券，本新聞稿不構成在美國或任何在該司法管轄區內此類要約、招攬或銷售在未符合或註冊該司法管轄區證券法之前的要約。根據此次發行提供的證券尚未，也不會根據美國證券法進行註冊，並且在未註冊或適用的美國註冊要求和適用的美國州證券法的豁免情況下，這些證券不得在美國境內或向美國人士提供或出售。</p>
<p><strong>關於 Profound Medical Corp.</strong></p>
<p>Profound 是一家商業階段的醫療設備公司，開發和銷售基於人工智能的、MRI 引導的、無切口的疾病組織消融療法。</p>
<p>Profound 正在商業化 TULSA-PRO®，這是一項結合實時 MRI、AI 增強規劃、機器人驅動的經尿道超聲和閉環温度反饋控制的技術。使用 TULSA-PRO 系統進行的 TULSA 程序™有潛力成為整個前列腺疾病譜的主流治療方式；涵蓋低、中、高風險前列腺癌；同時適用於同時患有前列腺癌和良性前列腺增生（“BPH”）的混合患者；僅患有 BPH 的男性；以及需要針對放射性復發局部前列腺癌進行挽救治療的患者。TULSA 程序採用實時 MRI 引導，以精確保護患者的尿失禁和性功能，同時通過精確的聲波吸收技術將目標前列腺組織加熱至 55-57°C。TULSA 是一種無切口和無輻射的 “一次性” 程序，在單次會話中完成，耗時數小時。幾乎所有形狀和大小的前列腺都可以安全、有效和高效地使用 TULSA 進行治療。該程序沒有出血；不需要住院；大多數 TULSA 患者報告迅速恢復到正常日常生活。TULSA-PRO 已獲得 CE 標記、加拿大衞生部批准，並獲得美國食品藥品監督管理局（“FDA”）的 510(k) 清關。</p>
<p>Profound 還在商業化 Sonalleve®，這是一種創新的治療平台，已獲得 CE 標記，用於治療子宮肌瘤、腺肌症、骨轉移疼痛緩解、纖維瘤和骨樣骨瘤。Sonalleve 還獲得了中國國家藥品監督管理局的批准，用於無創治療子宮肌瘤，並在美國獲得人道設備豁免下的 FDA 批准，用於治療骨樣骨瘤。Profound 正在早期階段探索 Sonalleve 的其他潛在治療市場，該技術已顯示出臨牀應用，例如無創消融腹部癌症和癌症治療的高温療法。</p>
<p><strong>前瞻性聲明</strong></p>
<p>本公告包含關於 Profound 及其業務的前瞻性聲明，這些聲明可能包括但不限於與公司預期的收益使用和發行結束相關的聲明。通常，但並非總是，前瞻性聲明可以通過使用諸如 “計劃”、“預計”、“期望”、“安排”、“打算”、“考慮”、“預期”、“相信”、“提議” 或這些詞語和短語的變體（包括否定變體）來識別，或者聲明某些行動、事件或結果 “可能”、“可以”、“將”、“可能會” 或 “將會” 被採取、發生或實現。這些聲明基於 Profound 管理層當前的預期。本公告中討論的前瞻性事件和情況，可能不會在某些特定日期之前發生，或者根本不會發生，並且可能因影響公司的已知和未知風險因素和不確定性而有實質性差異。儘管 Profound 已嘗試識別可能導致實際行動、事件或結果與前瞻性聲明中描述的內容有實質性差異的重要因素，但可能還有其他因素導致行動、事件或結果與預期、估計或打算的內容有所不同。沒有任何前瞻性聲明可以得到保證。可能導致實際結果與前瞻性聲明中所列內容有實質性差異的其他因素和風險已在 Profound 的 10-K 表格年度報告及其他向美國和加拿大證券監管機構提交的文件中進行了描述，這些文件可在 www.sedarplus.ca 和 www.sec.gov 獲取。除非適用的證券法要求，否則前瞻性聲明僅在作出聲明的日期有效，Profound 沒有義務公開更新或修訂任何前瞻性聲明，無論是由於新信息、未來事件還是其他原因，法律另有要求的除外。</p>
<p><strong>如需更多信息，請聯繫：</strong></p>
<p>Stephen Kilmer</p>
<p>投資者關係</p>
<p>skilmer@profoundmedical.com</p>
<p>電話：647.872.4849</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE56QXlOeU0zTXpNMU9UazFJekl3TVRnMU5EYz0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE56QXlOeU0zTXpNMU9UazFJekl3TVRnMU5EYz0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MjEwNzdjNjItZTFkOC00ZmE4LTlkMGItMjU4YjAxOTcwNzgxLTEwMzAxMTktMjAyNS0xMi0yNC1lbg==/tiny/Profound-Medical-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MjEwNzdjNjItZTFkOC00ZmE4LTlkMGItMjU4YjAxOTcwNzgxLTEwMzAxMTktMjAyNS0xMi0yNC1lbg==/tiny/Profound-Medical-Inc-.png"/></p>

PROF

<p>Profound Medical Corp. 已將其私募的規模擴大至最高 645 萬美元，計劃發行 921,428 股普通股，每股價格為 7.00 美元。募集資金將用於銷售和市場擴展、營運資金、研發、戰略交易以及一般企業用途。該發行預計將在 2025 年 12 月 30 日之前完成。股票的鎖定期為自交易完成之日起四個月加一天</p>

<p>TORONTO, Dec. 24, 2025 (GLOBE NEWSWIRE) -- <strong>Profound Medical Corp. (NASDAQ:PROF; TSX:PRN)</strong> (“Profound” or the “Company”) is pleased to announce that it has increased the size of its private placement previously announced on December 19, 2025 (the “Offering”) in order to accommodate participation by a long-term existing investor.</p>
<div class="lb-trans"><p>多倫多，2025 年 12 月 24 日（GLOBE NEWSWIRE）-- <strong>Profound Medical Corp. (NASDAQ:PROF; TSX:PRN)</strong>（“Profound” 或 “公司”）欣然宣佈，已增加其於 2025 年 12 月 19 日之前宣佈的私募配售規模（“發行”），以便容納一位長期現有投資者的參與。</p>
</div><p>The Company will now raise gross proceeds of up to US$6.45 million in the Offering, through the issuance of up to 921,428 common shares at a price of US$7.00 per common share.</p>
<div class="lb-trans"><p>公司現在將在此次發行中籌集最多 645 萬美元的毛收益，通過發行最多 921,428 股普通股，價格為每股 7.00 美元。</p>
</div><p>The common shares sold pursuant to the Offering will be subject to a hold period of four months plus one day from the closing date of the Offering. The closing of the Offering is expected to occur on or prior to December 30, 2025.</p>
<div class="lb-trans"><p>根據此次發行出售的普通股將受到四個月加一天的持有期限制，從發行的成交日期開始計算。預計此次發行的成交將在 2025 年 12 月 30 日或之前進行。</p>
</div><p>The Company intends to use the net proceeds from the Offering for expansion of its sales and marketing, working capital, research and development, strategic transactions and general corporate purposes.</p>
<div class="lb-trans"><p>公司打算將此次發行的淨收益用於擴大銷售和市場營銷、營運資金、研發、戰略交易和一般企業用途。</p>
</div><p>No securities will be sold under the Offering to United States purchasers and this press release is not an offer to sell or the solicitation of an offer to buy such securities in the United States or in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to qualification or registration under the securities laws of such jurisdiction. The securities being offered under the Offering have not been, nor will they be, registered under the U.S. Securities Act, and such securities may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from U.S. registration requirements and applicable U.S. state securities laws.</p>
<div class="lb-trans"><p>此次發行下不會向美國購買者出售任何證券，本新聞稿不構成在美國或任何在該司法管轄區內此類要約、招攬或銷售在未符合或註冊該司法管轄區證券法之前的要約。根據此次發行提供的證券尚未，也不會根據美國證券法進行註冊，並且在未註冊或適用的美國註冊要求和適用的美國州證券法的豁免情況下，這些證券不得在美國境內或向美國人士提供或出售。</p>
</div><p><strong>About Profound Medical Corp.</strong></p>
<div class="lb-trans"><p><strong>關於 Profound Medical Corp.</strong></p>
</div><p>Profound is a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue.</p>
<div class="lb-trans"><p>Profound 是一家商業階段的醫療設備公司，開發和銷售基於人工智能的、MRI 引導的、無切口的疾病組織消融療法。</p>
</div><p>Profound is commercializing TULSA-PRO®, a technology that combines real-time MRI, AI-enhanced planning, robotically-driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA Procedure™, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (“BPH”); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. The TULSA Procedure employs real-time MR guidance for precision to preserve patients’ urinary continence and sexual function, while killing the targeted prostate tissue via precise sound absorption technology that gently heats it to 55-57°C. TULSA is an incision- and radiation-free “one-and-done” procedure performed in a single session that takes a few hours. Virtually all prostate shapes and sizes can be safely, effectively, and efficiently treated with TULSA. There is no bleeding associated with the procedure; no hospital stay is required; and most TULSA patients report quick recovery to their normal routine. TULSA-PRO is CE marked, Health Canada approved, and 510(k) cleared by the U.S. Food and Drug Administration (“FDA”).</p>
<div class="lb-trans"><p>Profound 正在商業化 TULSA-PRO®，這是一項結合實時 MRI、AI 增強規劃、機器人驅動的經尿道超聲和閉環温度反饋控制的技術。使用 TULSA-PRO 系統進行的 TULSA 程序™有潛力成為整個前列腺疾病譜的主流治療方式；涵蓋低、中、高風險前列腺癌；同時適用於同時患有前列腺癌和良性前列腺增生（“BPH”）的混合患者；僅患有 BPH 的男性；以及需要針對放射性復發局部前列腺癌進行挽救治療的患者。TULSA 程序採用實時 MRI 引導，以精確保護患者的尿失禁和性功能，同時通過精確的聲波吸收技術將目標前列腺組織加熱至 55-57°C。TULSA 是一種無切口和無輻射的 “一次性” 程序，在單次會話中完成，耗時數小時。幾乎所有形狀和大小的前列腺都可以安全、有效和高效地使用 TULSA 進行治療。該程序沒有出血；不需要住院；大多數 TULSA 患者報告迅速恢復到正常日常生活。TULSA-PRO 已獲得 CE 標記、加拿大衞生部批准，並獲得美國食品藥品監督管理局（“FDA”）的 510(k) 清關。</p>
</div><p>Profound is also commercializing Sonalleve®, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids, adenomyosis, pain palliation of bone metastases, desmoid tumors and osteoid osteoma. Sonalleve has also been approved by the China National Medical Products Administration for the non-invasive treatment of uterine fibroids and has FDA approval under a Humanitarian Device Exemption for the treatment of osteoid osteoma. Profound is in the early stages of exploring additional potential treatment markets for Sonalleve where the technology has been shown to have clinical application, such as non-invasive ablation of abdominal cancers and hyperthermia for cancer therapy.</p>
<div class="lb-trans"><p>Profound 還在商業化 Sonalleve®，這是一種創新的治療平台，已獲得 CE 標記，用於治療子宮肌瘤、腺肌症、骨轉移疼痛緩解、纖維瘤和骨樣骨瘤。Sonalleve 還獲得了中國國家藥品監督管理局的批准，用於無創治療子宮肌瘤，並在美國獲得人道設備豁免下的 FDA 批准，用於治療骨樣骨瘤。Profound 正在早期階段探索 Sonalleve 的其他潛在治療市場，該技術已顯示出臨牀應用，例如無創消融腹部癌症和癌症治療的高温療法。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性聲明</strong></p>
</div><p>This release includes forward-looking statements regarding Profound and its business which may include, but is not limited to, statements relating to the Company’s anticipated use of proceeds and the closing of the Offering. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “is expected”, “expects”, “scheduled”, “intends”, “contemplates”, “anticipates”, “believes”, “proposes” or variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Such statements are based on the current expectations of the management of Profound. The forward-looking events and circumstances discussed in this release, may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company. Although Profound has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Other factors and risks that may cause actual results to differ materially from those set out in the forward-looking statements are described in Profound’s Annual Report on Form 10-K and other filings made with U.S. and Canadian securities regulators, available at www.sedarplus.ca and www.sec.gov. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Profound undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, other than as required by law.</p>
<div class="lb-trans"><p>本公告包含關於 Profound 及其業務的前瞻性聲明，這些聲明可能包括但不限於與公司預期的收益使用和發行結束相關的聲明。通常，但並非總是，前瞻性聲明可以通過使用諸如 “計劃”、“預計”、“期望”、“安排”、“打算”、“考慮”、“預期”、“相信”、“提議” 或這些詞語和短語的變體（包括否定變體）來識別，或者聲明某些行動、事件或結果 “可能”、“可以”、“將”、“可能會” 或 “將會” 被採取、發生或實現。這些聲明基於 Profound 管理層當前的預期。本公告中討論的前瞻性事件和情況，可能不會在某些特定日期之前發生，或者根本不會發生，並且可能因影響公司的已知和未知風險因素和不確定性而有實質性差異。儘管 Profound 已嘗試識別可能導致實際行動、事件或結果與前瞻性聲明中描述的內容有實質性差異的重要因素，但可能還有其他因素導致行動、事件或結果與預期、估計或打算的內容有所不同。沒有任何前瞻性聲明可以得到保證。可能導致實際結果與前瞻性聲明中所列內容有實質性差異的其他因素和風險已在 Profound 的 10-K 表格年度報告及其他向美國和加拿大證券監管機構提交的文件中進行了描述，這些文件可在 www.sedarplus.ca 和 www.sec.gov 獲取。除非適用的證券法要求，否則前瞻性聲明僅在作出聲明的日期有效，Profound 沒有義務公開更新或修訂任何前瞻性聲明，無論是由於新信息、未來事件還是其他原因，法律另有要求的除外。</p>
</div><p><strong>For further information, please contact:</strong></p>
<div class="lb-trans"><p><strong>如需更多信息，請聯繫：</strong></p>
</div><p>Stephen Kilmer</p>
<div class="lb-trans"><p>Stephen Kilmer</p>
</div><p>Investor Relations</p>
<div class="lb-trans"><p>投資者關係</p>
</div><p>skilmer@profoundmedical.com</p>
<div class="lb-trans"><p>skilmer@profoundmedical.com</p>
</div><p>T: 647.872.4849</p>
<div class="lb-trans"><p>電話：647.872.4849</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE56QXlOeU0zTXpNMU9UazFJekl3TVRnMU5EYz0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTYxNzAyNyM3MzM1OTk1IzIwMTg1NDc="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MjEwNzdjNjItZTFkOC00ZmE4LTlkMGItMjU4YjAxOTcwNzgxLTEwMzAxMTktMjAyNS0xMi0yNC1lbg==/tiny/Profound-Medical-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/MjEwNzdjNjItZTFkOC00ZmE4LTlkMGItMjU4YjAxOTcwNzgxLTEwMzAxMTktMjAyNS0xMi0yNC1lbg==/tiny/Profound-Medical-Inc-.png"/></p>

Profound Medical Corp.宣佈擴大私募規模 | PROF 股票新聞